Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in obesity-related HFpEF
NCT04788511Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2021
- Primary completion
- Apr 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 3 trial of semaglutide in heart failure with preserved ejection fraction (HFpEF), sponsored by Novo Nordisk. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04788511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04788511.